Clinical Trial

Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures

Study acronym: PACsign
Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this study is to assess the clinical value of 5 transcriptomic signatures prognostic of chemotherapeutic sensitivity to improve the Objective Response Rate (ORR) of first-line (L1). Chemotherapy regimen (FOLFIRINOX vs Gem-nabP) will be selected based on transcriptomic signatures applied to the pre-therapeutic liver biopsy of newly diagnosed PDAC patients.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-07-25; most recent amendment 2026-04-30.
Status change: Not Yet Recruiting → Recruiting 2022-12-16
Trial Details
NCT Number NCT05475366
Lead Sponsor Institut Curie
Conditions Carcinoma, Pancreatic Ductal, Prognosis
Enrollment 85 participants
Start Date 2022-12-12
Primary Completion 2028-12-11 (estimated)
Study Completion 2028-12-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-01